The CRISPR-cancer roller coaster continues
A group of scientists in Italy think they’ve got a way to solve CRISPR’s cancer issue, STAT’s Sharon Begley reports.
According to a study published Thursday, researchers have found a way to make sure that the genome editing system doesn’t accidentally cut out a gene that serves as a cellular fail-safe. That gene, p53, makes sure that changes — like the kind that get introduced by CRISPR/Cas9 — get caught and corrected. With the p53 gene intact, CRISPRed edits couldn’t stick; without it, cells are far more likely to become cancerous.
The three public CRISPR companies took a hit on the stock market back in June when the issue was first raised, but this new study did very little for them. Intellia, Editas, and CRISPR Therapeutics all closed up about 2 percent on Thursday.
Read more.
According to a study published Thursday, researchers have found a way to make sure that the genome editing system doesn’t accidentally cut out a gene that serves as a cellular fail-safe. That gene, p53, makes sure that changes — like the kind that get introduced by CRISPR/Cas9 — get caught and corrected. With the p53 gene intact, CRISPRed edits couldn’t stick; without it, cells are far more likely to become cancerous.
The three public CRISPR companies took a hit on the stock market back in June when the issue was first raised, but this new study did very little for them. Intellia, Editas, and CRISPR Therapeutics all closed up about 2 percent on Thursday.
Read more.
.png)
No hay comentarios:
Publicar un comentario